Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dig into DNA to unravel blood clot mysteries in rare disorder

NCT ID NCT05233384

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people with a rare inherited condition called dysfibrinogenemia, which affects how blood clots form. Researchers collected blood samples from 70 patients to analyze clot structure and search for genetic variations that might explain why some patients bleed while others develop dangerous clots. The goal is to better understand each person's unique clotting profile and eventually guide more personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors better predict whether a patient with dysfibrinogenemia is more likely to bleed or clot, leading to more personalized care.
What could go wrong
This is an observational study with only 70 participants, so findings may not apply to everyone. It is early-stage research, not a treatment trial, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Jul 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with confirmed hereditary dysfibrinogenemia

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with confirmed hereditary dysfibrinogenemia * Able to give his/her informed consent to participate * Affiliated to the French Health insurance Exclusion Criteria: * Refusal to participate * pregnant and breastfeeding women, * protected adults (individuals under guardianship by court order), * adults deprived of their liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary dysfibrinogenemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dysfibrinogenemia, Congenital familial dysfibrinogenemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary dysfibrinogenemia

Contacts and locations

Locations

  • CHU Dijon

    Dijon, France

  • CHU Montpellier

    Montpellier, France

  • CHU Nantes

    Nantes, France

  • CHU Tours

    Tours, France

  • CHU clermont-ferrand

    Clermont-Ferrand, France

  • CHU de Lille

    Lille, France

  • CHu Nancy

    Nancy, France